Zhixin Finance and Economics APP News, Olin Biology (688319.SH) announced that recently, the company has received the approval and issuance from the National Medical Products Administration for the《Notice of Approval for Clinical Trials of Trivalent Influenza Split Vaccines (MDCK Cells)》, allowing clinical trials to be conducted among people aged 6 months and older to prevent seasonal flu caused by influenza virus subtypes.

By developing a series of influenza vaccines, the company has successfully established a team and technical platform for virus vaccine research and development. The company's quadrivalent influenza split vaccine (MDCK cells) had previously obtained the《Notice of Approval for Clinical Trials of Drugs》from the National Medical Products Administration. The application for clinical trials of trivalent influenza split vaccine (MDCK cells) this time has been approved, which is a strong supplement to the company's influenza vaccine series. If the vaccine development is successful, it can provide a more diverse product range to meet market demand, enrich the company's product layout, and further enhance the company's market competitiveness.